The Institute for Clinical and Economic Review (ICER) has posted the draft report “Controversies in Migraine Management,” which will be the subject of deliberation and vote at the next public meeting of the CTAF on Friday, July 11 in Los Angeles, California.
Providing credible, evidence-based information about medical technologies, treatments, and models of care
CTAF has long been recognized as one of the leading technology assessment programs in the country. In 2013, CTAF became a core program of the Institute for Clinical and Economic Review, and its approach has now been adapted to broaden stakeholder engagement and improve the application of CTAF products in practice and policy. Learn more »
Attend a Meeting
July 11, 2014
Los Angeles, CA (Sheraton Gateway Hotel at LAX)
On July 11, 2014 CTAF examined various treatment options for migraine headaches. CTAF's review included evidence on the use of Botox for prevention and on the use of opioids for treatment in the emergency room. Also briefly reviewed were a new device for the prevention of migraines (Cefaly) and one for the treatment of migraines (SpringTMS by eNeura). CTAF’s public deliberation of the evidence will provide clarity and guidance to clinicians, insurers, and patients confronted with decisions on treatment of migraines.
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.